F9 and hemophilia B: This is exemplified by the first clinical trials for the treatment of severe hemophilia B, using an AAV2 vector carrying the gene for coagulation Factor IX (FIX) that was delivered either intramuscularly (34) or infused through the hepatic artery (35).